Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy-Reference-Cited by-同舟云学术

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

Published:2018-08-06 Issue:1 Volume:16 Page:45-63
ISSN:1759-4774
Container-title:Nature Reviews Clinical Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Mahadeo Kris M., ,Khazal Sajad J.^ORCID,Abdel-Azim Hisham,Fitzgerald Julie C.,Taraseviciute Agne,Bollard Catherine M.,Tewari Priti,Duncan Christine,Traube Chani^ORCID,McCall David,Steiner Marie E.,Cheifetz Ira M.,Lehmann Leslie E.,Mejia Rodrigo,Slopis John M.,Bajwa Rajinder,Kebriaei Partow,Martin Paul L.,Moffet Jerelyn,McArthur Jennifer,Petropoulos Demetrios,O’Hanlon Curry Joan,Featherston Sarah,Foglesong Jessica,Shoberu Basirat,Gulbis Alison,Mireles Maria E.,Hafemeister Lisa,Nguyen Cathy,Kapoor Neena,Rezvani Katayoun,Neelapu Sattva S.,Shpall Elizabeth J.

Abstract

AbstractIn 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which can lead to rapid cardiorespiratory and/or neurological deterioration. Multidisciplinary medical vigilance and the requisite health-care infrastructure are imperative to ensuring optimal patient outcomes, especially as these therapies transition from research protocols to standard care. Herein, authors representing the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program have collaborated to provide comprehensive consensus guidelines on the care of children receiving CAR T cell therapy.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://www.nature.com/articles/s41571-018-0075-2.pdf

Reference147 articles.

1. Noone, A. M. et al. SEER Cancer Statistics Review, 1975–2015. National Cancer Institute https://seer.cancer.gov/csr/1975_2015/ (2018).

2. Farber, S. & Diamond, L. K. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N. Engl. J. Med. 238, 787–793 (1948).

3. O’Leary, M., Krailo, M., Anderson, J. R. Reaman, G. H., & Children’s Oncology Group. Progress in childhood cancer: 50 years of research collaboration, a report from the Children’s Oncology Group. Semin. Oncol. 35, 484–493 (2008).

4. Blau, C. A. E. Donnall Thomas, M.D. (1920–2012). Stem Cells Transl Med. (2013).

5. Ko, R. H. et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J. Clin. Oncol. 28, 648–654 (2010).

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Further modification of the EASIX score through the addition of phosphorous and IL-6 improves prediction of CRS and ICANS after CAR-T therapy;2024-07-22

2. CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia;Heliyon;2024-07

3. Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia;Haematologica;2024-05-10

4. Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications;Heliyon;2024-04

5. The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?;Clinical Hematology International;2024-03-13